BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 27456662)

  • 1. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
    Guestini F; McNamara KM; Ishida T; Sasano H
    Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
    Nowacka-Zawisza M; Krajewska WM
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The functional role of Notch signaling in triple-negative breast cancer.
    Speiser JJ; Erşahin C; Osipo C
    Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer: molecular subtypes and new targets for therapy.
    Lehmann BD; Pietenpol JA; Tan AR
    Am Soc Clin Oncol Educ Book; 2015; ():e31-9. PubMed ID: 25993190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
    Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
    Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
    Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
    Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.